Opportunity Information: Apply for PAS 23 172
The National Institutes of Health, through the National Institute on Alcohol Abuse and Alcoholism (NIAAA), is offering the HIV Prevention and Alcohol (R34 Clinical Trials Optional) grant opportunity (Funding Opportunity Number PAS-23-172; CFDA 93.273). The core aim is to strengthen and diversify the HIV prevention toolkit for people and communities affected by alcohol use, including both episodic (for example, binge drinking) and longer-term patterns of alcohol involvement. The opportunity is built around the idea that alcohol can increase HIV acquisition risk through a mix of behavioral pathways (such as impaired judgment, higher likelihood of condomless sex, or reduced adherence to prevention strategies) and biological pathways (such as changes that may influence susceptibility or overall health). Projects supported under this announcement are expected to advance prevention by integrating effective prevention and treatment approaches and by generating cross-cutting, practical research insights that ultimately help reduce the number of new HIV infections.
This announcement uses the R34 mechanism, which is designed specifically for planning and preparatory research that directly enables a later clinical trial. The intent is not to run a full-scale efficacy or implementation trial under the R34 itself, but to fund the studies that are necessary and sufficient to design a strong, feasible, and well-justified trial that would fall under the companion HIV Prevention and Alcohol (R01 Clinical Trials Optional) announcement. In other words, applicants are expected to lay out the clinical trial they intend to conduct later and make a clear case that the R34 work is essential to finalizing that trial design. NIAAA is looking for projects where the R34 findings will be enough to move into the next-stage trial without needing additional preliminary studies.
The future trial that the R34 is preparing for must be a Phase II, III, or IV clinical trial, and its primary purpose must be to test an intervention related to HIV prevention. That could include testing efficacy, safety, clinical management approaches, or implementation strategies for prevention interventions. The R34-funded work can focus on answering scientific and operational questions that are often pragmatic in nature, such as how to recruit and retain alcohol-impacted populations, how to deliver an intervention in real-world settings, what adaptations are needed for a specific community or service environment, what outcome measures are most appropriate, or what procedures ensure fidelity and feasibility. The overall expectation is that the pilot or planning work will meaningfully de-risk the subsequent trial by resolving uncertainties that would otherwise undermine trial success.
Eligibility is broad and includes many types of organizations and institutions. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (excluding institutions of higher education for those categories as specified); for-profit organizations other than small businesses; small businesses; and other entities. The announcement also highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-U.S. entities (foreign organizations). This wide eligibility reflects the program’s interest in supporting research that is well-positioned in diverse communities and service systems, including those disproportionately affected by HIV and alcohol-related harms.
Administratively, this is a discretionary grant opportunity under the NIH, categorized under the Health funding activity area. The original closing date listed for the opportunity is 2026-05-07, and the FOA was created on 2023-05-12. An award ceiling is not specified in the provided source information, and the expected number of awards is not listed. The practical takeaway is that applicants should focus on building a compelling planning package: a clearly described future HIV prevention trial, a tight justification for why the R34 activities are required to finalize that trial, and a set of deliverables that will directly inform and enable the later Phase II-IV study in alcohol-impacted populations.Apply for PAS 23 172
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "HIV Prevention and Alcohol (R34 Clinical Trials Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.273.
- This funding opportunity was created on 2023-05-12.
- Applicants must submit their applications by 2026-05-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs): HIV Prevention and Alcohol (R34 Clinical Trials Optional)
What is this funding opportunity?
This opportunity is the NIH-funded grant titled HIV Prevention and Alcohol (R34 Clinical Trials Optional), offered through the National Institute on Alcohol Abuse and Alcoholism (NIAAA). The Funding Opportunity Number is PAS-23-172 and the CFDA listing provided is 93.273.
What is the main goal of the program?
The core goal is to strengthen and diversify the HIV prevention toolkit for people and communities affected by alcohol use. This includes both episodic alcohol use (for example, binge drinking) and longer-term patterns of alcohol involvement. Supported projects are expected to generate practical insights that help reduce new HIV infections by addressing alcohol-related factors that increase HIV acquisition risk.
Why does the program focus on alcohol in the context of HIV prevention?
The announcement is based on the idea that alcohol can increase HIV acquisition risk through a combination of behavioral pathways (such as impaired judgment, increased likelihood of condomless sex, or reduced adherence to prevention strategies) and biological pathways (such as changes that may influence susceptibility or overall health). The program aims to translate this understanding into better HIV prevention approaches for alcohol-impacted populations.
What does the R34 mechanism support under this announcement?
The R34 mechanism is designed for planning and preparatory research that directly enables a later clinical trial. Under this announcement, the R34 is intended to fund the studies that are necessary and sufficient to design a strong, feasible, and well-justified HIV prevention clinical trial that would be pursued later under the companion HIV Prevention and Alcohol (R01 Clinical Trials Optional) announcement.
Is this R34 meant to fund a full clinical trial?
No. The intent is not to run a full-scale efficacy or implementation trial under the R34 itself. Instead, the R34 should support the planning, pilot, and preparatory work needed to finalize the design of a future Phase II-IV trial.
What kind of future clinical trial is the R34 expected to prepare for?
The future trial must be a Phase II, III, or IV clinical trial. Its primary purpose must be to test an intervention related to HIV prevention, which may include testing efficacy, safety, clinical management approaches, or implementation strategies for prevention interventions.
Do applicants need to describe the future clinical trial in the R34 application?
Yes. Applicants are expected to lay out the clinical trial they intend to conduct later and make a clear case that the R34 work is essential to finalizing that trial design.
What is NIAAA looking for in terms of readiness after the R34 ends?
NIAAA is looking for projects where the R34 findings will be enough to move directly into the next-stage trial without needing additional preliminary studies. The R34 should resolve key uncertainties that would otherwise undermine the success of the later Phase II-IV clinical trial.
What types of research questions can the R34 support?
The R34-funded work can address scientific and operational questions that are often pragmatic in nature, including:
- How to recruit and retain alcohol-impacted populations
- How to deliver an intervention in real-world settings
- What adaptations are needed for a specific community or service environment
- What outcome measures are most appropriate
- What procedures ensure fidelity and feasibility
What does it mean to "de-risk" the later trial?
In this context, de-risking means using R34 planning and pilot activities to resolve uncertainties that could derail a Phase II-IV HIV prevention trial. The expectation is that the R34 will produce concrete deliverables that make the later trial feasible, well-justified, and operationally workable in alcohol-impacted populations.
What kinds of populations is this opportunity intended to benefit?
The opportunity is centered on people and communities affected by alcohol use, including episodic and longer-term patterns of alcohol involvement. It also emphasizes research that is positioned in diverse communities and service systems, including those disproportionately affected by HIV and alcohol-related harms.
What types of organizations are eligible to apply?
Eligibility is broad. Eligible applicants include:
- State, county, city, or township governments
- Special district governments
- Independent school districts
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Federally recognized Native American tribal governments
- Native American tribal organizations that are not federally recognized
- Public housing authorities and Indian housing authorities
- Nonprofits (with or without 501(c)(3) status), as specified in the announcement
- For-profit organizations (other than small businesses)
- Small businesses
- Other entities
Are community-based, faith-based, and minority-serving organizations eligible?
Yes. The announcement highlights additional eligible applicants including faith-based or community-based organizations, as well as a range of minority-serving institutions such as HBCUs, Hispanic-serving Institutions, AANAPISIs, TCCUs, and Alaska Native and Native Hawaiian Serving Institutions.
Are non-U.S. organizations allowed to apply?
Yes. The eligibility list includes non-U.S. entities (foreign organizations).
Are U.S. territories or possessions included in eligibility?
Yes. The announcement lists U.S. territories or possessions among the eligible applicants.
Which agency and institute are sponsoring this opportunity?
This is a discretionary grant opportunity under the National Institutes of Health (NIH), administered through the National Institute on Alcohol Abuse and Alcoholism (NIAAA). It is categorized under the Health funding activity area.
What is the Funding Opportunity Number (FOA number) and CFDA listing?
The Funding Opportunity Number is PAS-23-172. The CFDA listing provided is 93.273.
When was the FOA created and what is the listed closing date?
The FOA was created on 2023-05-12. The original closing date listed is 2026-05-07.
Is there an award ceiling listed?
No award ceiling is specified in the provided information.
Is the expected number of awards listed?
No. The expected number of awards is not listed in the provided information.
What should applicants focus on if funding levels and award counts are not specified?
Based on the provided information, the practical focus should be on building a compelling planning package: a clearly described future HIV prevention trial, a tight justification for why the R34 activities are required to finalize that trial, and deliverables that directly inform and enable the later Phase II-IV study in alcohol-impacted populations.
How does this R34 relate to the companion R01 announcement?
The R34 is explicitly described as preparatory work that enables a later clinical trial that would fall under the companion HIV Prevention and Alcohol (R01 Clinical Trials Optional) announcement. The R34 should produce the planning and pilot results needed to justify and launch that next-stage trial.
What does "Clinical Trials Optional" mean here?
The provided description emphasizes that the R34 is meant for planning and preparatory research that enables a later clinical trial, rather than running a full-scale trial under the R34 itself. The future trial being prepared for must be Phase II-IV and focused on HIV prevention interventions.
Browse more opportunities from the same category: Health
Next opportunity: EPSCoR Collaborations for Optimizing Research Ecosystems Research Infrastructure Improvement Program
Previous opportunity: FY23 IIJA Department of the Interior - Bureau of Land Management Montana/Dakota Good Neighbor Authority
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAS 23 172
Applicants also applied for:
Applicants who have applied for this opportunity (PAS 23 172) also looked into and applied for these:
| Funding Opportunity |
|---|
| Alcohol Health Services Research (R01 Clinical Trial Optional) Apply for PAR 23 185 Funding Number: PAR 23 185 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alcohol Health Services Research (R34 Clinical Trial Optional) Apply for PAR 23 186 Funding Number: PAR 23 186 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alcohol Treatment and Recovery Research (R01 Clinical Trial Required) Apply for PAR 23 187 Funding Number: PAR 23 187 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Early-Stage Therapy Development for Alzheimer's Disease-Related Dementias (ADRD) (R61/R33 - Clinical Trial Not Allowed) Apply for RFA NS 24 010 Funding Number: RFA NS 24 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alcohol Treatment and Recovery Research (R34 Clinical Trial required) Apply for PAR 23 188 Funding Number: PAR 23 188 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Analyzing Early Events in TB and TB/HIV Infection for Interventional Targets (R01 Clinical Trial Not Allowed) Apply for RFA AI 23 029 Funding Number: RFA AI 23 029 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Collaborative Opportunities for Multidisciplinary, Bold, and Innovative Neuroscience (COMBINE) (RM1 Clinical Trial Optional) Apply for RFA NS 23 027 Funding Number: RFA NS 23 027 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding Gene-Environment Interactions in Brain Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Not Allowed) Apply for RFA AG 24 021 Funding Number: RFA AG 24 021 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Bioinformatics Resource Centers (BRCs) for Infectious Diseases (U24 Clinical Trials Not Allowed) Apply for RFA AI 23 032 Funding Number: RFA AI 23 032 Agency: National Institutes of Health Category: Health Funding Amount: $2,500,000 |
| Preclinical Studies to Characterize the Impact of Toxicants on Brain Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Not Allowed) Apply for RFA AG 24 023 Funding Number: RFA AG 24 023 Agency: National Institutes of Health Category: Health Funding Amount: $1,250,000 |
| Quantifying the Impact of Environmental Toxicants on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Risk in Cohort Studies (U01 Clinical Trial Not Allowed) Apply for RFA AG 24 022 Funding Number: RFA AG 24 022 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Significance of Clonal Hematopoiesis (CH) in Aging Humans (R01 Clinical Trial Not Allowed)? Apply for RFA AG 24 038 Funding Number: RFA AG 24 038 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Measuring Financial Hardship Among People and Families Living with AD/ADRD (R01 Clinical Trial Not Allowed)? Apply for RFA AG 24 036 Funding Number: RFA AG 24 036 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Health Information Systems (HIS) Activity Apply for 72052123RFI00001 Funding Number: 72052123RFI00001 Agency: Haiti USAID-Port Au Prince Category: Health Funding Amount: Case Dependent |
| Assessment of TBI-related ADRD Pathology Related to Cognitive Impairment and Dementia Outcomes (U01 - Clinical Trial Not Allowed) Apply for RFA NS 24 003 Funding Number: RFA NS 24 003 Agency: National Institutes of Health Category: Health Funding Amount: $1,300,000 |
| Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed) Apply for PAR 23 211 Funding Number: PAR 23 211 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Investigating Distinct and Overlapping Mechanisms in TDP-43 Proteinopathies, including in LATE, FTD and other ADRDs (R01 - Clinical Trial Not Allowed) Apply for PAR 23 212 Funding Number: PAR 23 212 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| NIMHD Centers of Excellence in Investigator Development and Community Engagement (P50 - Clinical Trial Optional) Apply for RFA MD 23 011 Funding Number: RFA MD 23 011 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Accelerating Behavioral and Social Science through Ontology Development and Use: Dissemination and Coordination Center (U24) Clinical Trial Not Allowed Apply for PAR 23 181 Funding Number: PAR 23 181 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Specialized Alcohol Research Centers (P50 Clinical trial Optional) Apply for RFA AA 23 001 Funding Number: RFA AA 23 001 Agency: National Institutes of Health Category: Health Funding Amount: $1,150,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAS 23 172", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.